Irish Drugmaker Elan to Spin Off Research Unit

The decision to split the company comes hard on the heels of the failure of an experimental Alzheimer’s drug being developed with Pfizer and Johnson & Johnson, although Chief Executive Kelly Martin said it had been planned for more than a year.
Reuters